One fund channels profits to breast cancer research, while the other focuses on established drugmakers. See how their strategies shape risk and sector exposure.

One of the biggest misconceptions about ETFs is that they are highly diversified “baskets” of stocks. Sometimes they are. But ...

IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, ...

A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.

Half of every dollar invested in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) rides on just two companies pulling in opposite directions in 2026. With a 0.38% expense ratio, nearly $1.1 billion in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...